{"entity":{"id":"medilink","kind":"company","name":"MediLink Therapeutics","aka":["MediLink Therapeutics (Suzhou)","MediLink Therapeutics"],"tldr":"MediLink developed the TMALIN ADC linker platform, licensed to Zai Lab, BioNTech, and Roche.","summary":"MediLink Therapeutics, based in Suzhou, developed the TMALIN antibody-drug conjugate linker platform, which it has licensed to Zai Lab, BioNTech and Roche. Its pipeline includes YL201, a B7-H3 ADC in phase 3 in small-cell lung cancer, ZL-6201 against LRRC15 with Zai Lab, and a c-MET ADC deal with Roche. OnCo links it to B7-H3 as a target and to Zai Lab as a partner. Whether a linker platform company can hold on to its own lead programme rather than out-license everything is the open question. The B7-H3 target page carries the competitive picture.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.medilinkthera.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":["b7h3"],"drugs":["yl201","yl202"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06459973","nct05434234","nct07197827","nct07258979","nct07208773","nct07169994","nct06241846","nct07202364","nct06107686","nct06439771","nct06057922"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.medilinkthera.com","investors":[],"funding":[]},"route":"/companies/medilink/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"}],"drug":[{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"},{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/"}],"trial":[{"id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/"},{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/"},{"id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/"},{"id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/"},{"id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/"},{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/"},{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/"},{"id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/"},{"id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/"},{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/"},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/"},{"id":"nct06107686","kind":"trial","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","route":"/trials/nct06107686/"},{"id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/"},{"id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","route":"/trials/nct07803783/"},{"id":"nct06057922","kind":"trial","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","route":"/trials/nct06057922/"},{"id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/"},{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/"}],"company":[{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}]}}